Breaking News Instant updates and real-time market news.

AMZN

Amazon.com

$902.06

2.86 (0.32%)

, AAPL

Apple

$142.44

1.76 (1.25%)

11:29
04/21/17
04/21
11:29
04/21/17
11:29

Tech giants focus lobbying dollars on combating Trump, Recode says

Tech companies such as Amazon (AMZN), Apple (AAPL), Facebook (FB), Google (GOOG), and Microsoft (MSFT) have focused some of their lobbying sumes in Washington over the past three months on fighting U.S. president Donald Trump, as he looked toward major changes to the U.S. tax code and placed new restriction on foreign immigrants, Recode reports. Both issues are present on many firms' Q1 lobbying reports, the report notes. The five aforementioned companies spent a combined $13.3M to influence regulators in D.C. between January 1 and March 31, the report says, citing records. Reference Link

AMZN

Amazon.com

$902.06

2.86 (0.32%)

AAPL

Apple

$142.44

1.76 (1.25%)

FB

Facebook

$143.80

1.53 (1.08%)

GOOG

Alphabet

$841.65

3.44 (0.41%)

GOOGL

Alphabet Class A

$860.08

3.57 (0.42%)

MSFT

Microsoft

$65.50

0.46 (0.71%)

  • 27

    Apr

  • 27

    Apr

  • 27

    Apr

  • 27

    Apr

  • 02

    May

  • 02

    May

  • 03

    May

  • 09

    May

  • 16

    May

  • 22

    May

  • 23

    May

AMZN Amazon.com
$902.06

2.86 (0.32%)

04/20/17
04/20/17
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Amazon.com (AMZN) downgraded to Peer Perform from Outperform at Wolfe Research with analyst Scott Mushkin saying shares are approaching his price target and he expects increasing competition through year-end. 2. Time Warner (TWX) downgraded to Hold from Buy at Pivotal Research with analyst Brian Wieser saying shares are trading near the value of AT&T's (T) offering price. 3. Molson Coors (TAP) downgraded to Market Perform from Outperform at Cowen with analyst Vivien Azer citing expectations for persistent beer volume headwinds. The analyst believes alcohol consumption could be pressured for at least the next decade, partly due to increased cannabis use, and a contraction in the alcohol cycle. Azer said Molson is uniquely exposed to the increasingly vibrant and growing cannabis markets and notes there is an inverse relationship between cannabis use and alcohol consumption over time. 4. eBay (EBAY) downgraded to Neutral from Buy at Monness Crespi with analyst James Cakmak saying he sees insufficient upside to estimates to justify the lofty valuation. The analyst said the path to double-digit growth may be pushed out 2019 and limited potential to outperform topline expectations in 2017. Further, the analyst sees margin pressures from product mix towards StubHub and rising development spend for the backend, and limited opportunities for multiple expansion. 5. Ruth's Hospitality (RUTH) downgraded to Market Perform from Outperform at Raymond James with analyst Brian Vaccaro citing valuation. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
04/21/17
LEHM
04/21/17
UPGRADE
Target $185
LEHM
Overweight
Costco upgraded to Overweight from Equal Weight at Barclays
Barclays analyst Karen Short upgraded Costco Wholesale (COST) to Overweight after her survey of 800 customers indicated more than 80% of them go to Costco stores specifically for food. This suggests the company is "very protected" from Amazon (AMZN), Short tells investors in a research note. The analyst expects Costco's traffic to accelerate amid easing comparisons into the second half of the year. Short also sees the potential for a special dividend from a tax break on foreign cash repatriation. She raised her price target for the shares to $185 from $170.
04/21/17
PIPR
04/21/17
NO CHANGE
Target $1000
PIPR
Overweight
Amazon.com Q2 margin guidance may miss consensus, says Piper Jaffray
Piper Jaffray analyst Michael Olson expects Amazon.com on April 27 to report Q1 results in-line with expectations. He believes, however, that its Q2 margin guidance may be slightly below consensus. This is consistent with most investor expectations, Olson tells investors in a pre-earnings research note. The analyst believes long-term investors should own Amazon through the Q1 earnings report. He reiterates an Overweight rating on the shares with a $1,000 price target.
04/20/17
WOLF
04/20/17
DOWNGRADE
WOLF
Peer Perform
Amazon downgraded by Wolfe Research with 'retail bloodbath' seen ahead
As previously reported, Wolfe Research downgraded Amazon.com to Peer Perform from Outperform. Analyst Scott Mushkin said shares are approaching his price target and he expects increasing competition through year-end. He expects next year to be a "bloodbath" in retail due to increased competition from Wal-Mart (WMT), traditional consumable operators, and other broadlines/specialty retailers, leading to a deceleration in Amazon sales, he tells investors. Mushkin reduced his FY17 earnings estimate to $6.52 from $6.63 and FY18 to $9.92 from $10.09 due mostly to lowered expectations in North America.
AAPL Apple
$142.44

1.76 (1.25%)

04/20/17
WELS
04/20/17
NO CHANGE
WELS
Market Perform
Apple has 'modest' margin risk from ongoing Qualcomm fight, says Wells Fargo
Wells Fargo analyst Maynard Um noted that Apple (AAPL) has acknowledged it withheld payments to its contract manufacturers in the amount that it felt Qualcomm (QCOM) owed it under a separate cooperation agreement, but that Qualcomm "seems to believe," based on its earnings call comments, that the manufacturers will eventually pay what's contractually owed. With the cooperation agreement having ended at the end of 2016, it remains unclear if Apple will have to pay its contract manufacturers the cited $1B over three quarters, which leaves "modest risk" on the possibility for an increase in cost of goods and associated hit to gross margins, said Um, who has a Market Perform rating on Apple shares.
04/20/17
UBSW
04/20/17
NO CHANGE
Target $58
UBSW
Neutral
Qualcomm guidance not as bad as feared, says UBS
UBS analyst Stephen Chin noted Qualcomm (QCOM) reported a strong Q2 beat but he maintained his Neutral rating due to uncertainty over future Apple (AAPL) payments as its lawsuit remains unresolved and it disclosed there is a new underpaying licensee. Chin said fundamentals remain mixed near-term, but added that the company's guidance was not as bad as feared. Chin has a $58 price target on Qualcomm shares.
04/20/17
STFL
04/20/17
NO CHANGE
STFL
Apple price target raised to $150 from $130 at Stifel
Stifel analyst Aaron Rakers continues to expect Apple to report in-line Q2 results. However, he raised his 2017 and 2018 estimates for the company ,citing historical data on the percent of the iPhone installed base that bought the newest iPhones and the ratio of new iPhones shipped to total iPhone sales. However, Rakers keeps a Hold rating on the stock.
04/21/17
OPCO
04/21/17
NO CHANGE
OPCO
Perform
Verizon responding to wireless competition, says Oppenheimer
Oppenheimer analyst Timothy Horan expects Verizon's (VZ) equipment revenue in Q4 to be strong, linked to the release of the new iconic Apple (AAPL) iPhone 8. The analyst believes wireless competition will remain elevated, but Verizon is responding, and will remained focused on network quality. Further, Horan says Verizon is integrating Yahoo (YHOO)/AOL to deliver growth from programmatic ads/digital content, but this will take some time. He reiterates a Perform rating on Verizon's shares.
FB Facebook
$143.80

1.53 (1.08%)

04/19/17
MSCN
04/19/17
NO CHANGE
MSCN
Facebook overall trends remain 'very strong,' says MScience
MScience analyst Steven Weinstein is forecasting Facebook's North American revenues of 4.07B, down slightly from $4.08B, above consensus of $4.005B. The analyst said slowing increases in US spending per advertiser led to a modest deceleration in revenue growth, but these trends are reflected in management's comments regarding ad load leveling off. Weinstein views overall trends as "very strong."
04/17/17
AGIS
04/17/17
NO CHANGE
Target $160
AGIS
Buy
Facebook price target raised to $160 ahead of F8, earnings at Aegis
Aegis analyst Victor Anthony said he expects Facebook's annual "F8" developer conference this week and the company's Q1 earnings report on May 3 to both be catalysts for the stock and raised his price target on the shares to $160 from $155 ahead of the events. He expects F8 to focus on innovations with the camera and video and he predicts the company will report solid quarterly results given strong advertiser checks. Anthony keeps a Buy rating on Facebook shares.
04/21/17
MKMP
04/21/17
NO CHANGE
MKMP
Facebook Q1 results likely to beat expectations, says MKM Partners
MKM Partners analyst Rob Sanderson expects Facebook's Q1 results to beat expectations, and he believes that the company's "tone" on the the likely deceleration of ad load growth in 2H17 has "softened." He adds that user growth and engagement will continue to be an area of focus, given "greater focus" on competition from Snapchat (SNAP). However, he continues to believe that Facebook is "a core holding for growth investors" and keeps a Buy rating.
04/17/17
FBCO
04/17/17
NO CHANGE
Target $175
FBCO
Outperform
Facebook price target raised to $175 from $170 at Credit Suisse
Credit Suisse analyst Stephen Ju raised his price target for Facebook to $175 from $170 ahead of Q1 results, and as he increases his ad volume growth estimates for 2H17 from what he felt was "an excessively conservative" level, offset by higher anticipated content spend. The analyst reiterates an Outperform rating on the shares.
GOOG Alphabet
$841.65

3.44 (0.41%)

04/11/17
04/11/17
UPGRADE
Target $43

Overweight
Yelp upgraded to Overweight on 'underappreciated core' at Pacific Crest
As previously reported, Pacific Crest analyst Brad Erickson upgraded Yelp (YELP) to Overweight from Sector Weight, saying his checks with local ad customers indicate Yelp's core franchise is healthy and appears insulated from larger competitors like Google (GOOG) and Facebook (FB). Over $60B of offline local ad spending is shifting toward online and Yelp remains well-positioned to capitalize on this trend, though its core business is underappreciated in the shares' current value, said Erickson, who has a $43 price target on the stock.
04/12/17
JMPS
04/12/17
NO CHANGE
JMPS
MINDBODY partnership positive, says JMP Securities
JMP Securities analyst Patrick Walravens says that MINDBODY's (MB) partnership with Google (GOOG, GOOGL) will enable MINDBODY's subscribers "to use dynamic pricing," and allow the company to increase its revenue by charging subscribers "a 10% fee for the booking and a 1% fee for the payment processing." The analyst keeps a $32 price target and an Outperform rating on MINDBODY.
04/13/17
COWN
04/13/17
NO CHANGE
Target $60
COWN
Outperform
Criteo price target raised to $60 from $55 at Cowen
Cowen analyst Thomas Champion raised his price target on Criteo (CRTO) to $60 from $55 as he believes the company is well positioned in the near term given recent AdTech moves by Facebook (FB) and Alphabet (GOOG). He sees header bidding adoption as opening more inventory and sees the long-term potential for more competition. Champion raised his estimates to account for the seasonal impact in revenues versus more linear growth in expenses while reiterating his Outperform rating on Criteo shares.
04/17/17
FBCO
04/17/17
NO CHANGE
Target $1100
FBCO
Outperform
Credit Suisse remains bullish on Alphabet ahead of Q1 results
Credit Suisse analyst Stephen Ju notes that Alphabet's shares have underperformed relative to its Internet large cap peers in 2016 and 2017 year to date. Nonetheless, he points out that even as the sheer size of its search business continues to blunt the contributions from other businesses, YouTube, Play, and Cloud collectively should be contributing about 1/3 of Net Revenue within three years. Further, the analyst anticipates free cash flow to grow at about 17.5% CAGR over the next five years, and therefore argues that Alphabet Class A shares should trade higher. Ju reiterates an Outperform rating and $1100 price target on the shares.
GOOGL Alphabet Class A
$860.08

3.57 (0.42%)

04/20/17
PACS
04/20/17
NO CHANGE
PACS
Alphabet checks positive, says Pacific Crest
Checks with advertisers indicate that "search remains very strong" for Alphabet, while advertisers' feedback on YouTube "remained very positive," according to Pacific Crest analyst Andy Hargreaves. He keeps a $1,040 price target on the shares and recommends buying the stock.
MSFT Microsoft
$65.50

0.46 (0.71%)

03/17/17
PACS
03/17/17
NO CHANGE
PACS
Growth of Amazon.com cloud business could moderate, says Pacific Crest
Pacific Crest analyst Brent Bracelin says that heavy investments by Microsoft (MSFT) and Google (GOOG, GOOGL) could make their cloud businesses more competitive with Amazon's (AMZN) AWS. The analyst says that AWS' growth could decelerate this year and in 2018. He lowered his estimates for Amazon and cut his price target on the name to $895 from $905 but keeps an Overweight rating on the shares.
04/13/17
RBCM
04/13/17
NO CHANGE
RBCM
Microsoft Q4 guidance likely to rise, says RBC Capital
RBC Capital expects Microsoft's Q4 guidance to improve, "driven by improving transactional business, good commercial cloud gross margins and modestly better PC data."
03/20/17
JMPS
03/20/17
NO CHANGE
JMPS
Tableau weakness creates buying opportunity, says JMP Securities
JMP Securities analyst Greg McDowell says that investors' worries about Tableau's (DATA) intensifying competition are overdone. The analyst thinks that the company has a significant lead over its competitions, while many enterprises are starting to use analytics. The analyst adds that, although Microsoft (MSFT) has become a tougher competitor, the competition from Qlik and TIBCO Sportfire has eased. The analyst says that the weakness in Tableau's stock has created a buying opportunity, and he keeps a $65 price target and an Outperform rating on Tableau.
03/17/17
PACS
03/17/17
NO CHANGE
PACS
Feedback on Microsoft cloud more positive, says Pacific Crest
Microsoft's (MSFT) cloud partners have become more upbeat on the company's cloud business, Azure, according to Pacific Crest analyst Brent Bracelin. The analyst says that Azure has "become a viable alternative to" Amazon's (AMZN) AWS. He continues to recommend buying Microsoft stock. .

TODAY'S FREE FLY STORIES

ABBV

AbbVie

$63.82

0.04 (0.06%)

, ALXN

Alexion

$116.82

-1.9 (-1.60%)

04:55
04/23/17
04/23
04:55
04/23/17
04:55
Conference/Events
European Association for the Study of Liver »

International Liver…

ABBV

AbbVie

$63.82

0.04 (0.06%)

ALXN

Alexion

$116.82

-1.9 (-1.60%)

BAX

Baxter

$52.88

-0.01 (-0.02%)

CPHD

Cepheid

GALT

Galectin Therapeutics

$3.09

-0.14 (-4.33%)

GILD

Gilead

$65.93

-0.57 (-0.86%)

ICPT

Intercept

$107.89

0.7 (0.65%)

JWA

John Wiley & Sons; also tag JWB

NVS

Novartis

$73.40

-0.22 (-0.30%)

OSUR

OraSure

$12.67

0.03 (0.24%)

SIEGY

Siemens

$67.34

-0.197 (-0.29%)

VTL

Vital Therapies

$3.50

-0.1 (-2.78%)

ARWR

Arrowhead

$1.52

0.01 (0.66%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Apr

  • 27

    Apr

  • 27

    Apr

  • 02

    May

  • 02

    May

  • 02

    May

  • 03

    May

  • 03

    May

  • 16

    May

  • 06

    Jun

  • 26

    Jun

  • 23

    Oct

AAPL

Apple

$142.27

-0.17 (-0.12%)

, FB

Facebook

$143.68

-0.12 (-0.08%)

13:57
04/22/17
04/22
13:57
04/22/17
13:57
Hot Stocks
Week in review: How Trump's policies moved stocks »

Catch up on the top…

AAPL

Apple

$142.27

-0.17 (-0.12%)

FB

Facebook

$143.68

-0.12 (-0.08%)

GOOG

Alphabet

$843.19

1.54 (0.18%)

GOOGL

Alphabet Class A

$858.95

-1.13 (-0.13%)

AMZN

Amazon.com

$898.53

-3.53 (-0.39%)

MSFT

Microsoft

$66.40

0.9 (1.37%)

STLD

Steel Dynamics

$35.37

0.46 (1.32%)

AKS

AK Steel

$6.72

-0.1 (-1.47%)

X

U.S. Steel

$30.42

-0.09 (-0.29%)

NUE

Nucor

$60.00

-0.35 (-0.58%)

CYH

Community Health

$8.24

-0.11 (-1.32%)

HCA

HCA Holdings

$83.55

-0.57 (-0.68%)

LPNT

LifePoint

$60.85

-0.7 (-1.14%)

THC

Tenet

$15.35

0.36 (2.40%)

UHS

Universal Health

$118.84

-0.29 (-0.24%)

HUM

Humana

$213.67

-0.57 (-0.27%)

BAC

Bank of America

$22.71

-0.36 (-1.56%)

C

Citi

$57.72

-0.69 (-1.18%)

GS

Goldman Sachs

$216.86

-1.2 (-0.55%)

JPM

JPMorgan

$84.52

-1.03 (-1.20%)

MS

Morgan Stanley

$41.80

-0.7 (-1.65%)

USB

U.S. Bancorp

$50.51

-0.17 (-0.34%)

WFC

Wells Fargo

$53.00

-0.5 (-0.93%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

  • 25

    Apr

  • 25

    Apr

  • 25

    Apr

  • 26

    Apr

  • 26

    Apr

  • 26

    Apr

  • 27

    Apr

  • 27

    Apr

  • 27

    Apr

  • 27

    Apr

  • 27

    Apr

  • 28

    Apr

  • 02

    May

  • 02

    May

  • 02

    May

  • 02

    May

  • 02

    May

  • 03

    May

  • 03

    May

  • 03

    May

  • 09

    May

  • 09

    May

  • 11

    May

  • 16

    May

  • 16

    May

  • 19

    May

  • 22

    May

  • 22

    May

  • 23

    May

  • 25

    May

  • 06

    Jun

  • 06

    Jun

  • 13

    Jun

  • 13

    Jul

  • 14

    Jul

  • 18

    Jul

  • 19

    Jul

  • 25

    Jul

  • 12

    Oct

  • 12

    Oct

  • 17

    Oct

  • 18

    Oct

  • 15

    Jan

  • 17

    Jan

  • 13

    Apr

  • 13

    Jul

  • 12

    Oct

JNS

Janus Capital

$13.15

-0.07 (-0.53%)

13:27
04/22/17
04/22
13:27
04/22/17
13:27
Conference/Events
Janus Capital to host special shareholder meeting »

Special Shareholder…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

ABT

Abbott

$43.53

-0.45 (-1.02%)

, ABBV

AbbVie

$63.82

0.04 (0.06%)

04:55
04/22/17
04/22
04:55
04/22/17
04:55
Conference/Events
National Kidney Foundation to hold clinical meeting »

NKF 2017 Spring Clinical…

ABT

Abbott

$43.53

-0.45 (-1.02%)

ABBV

AbbVie

$63.82

0.04 (0.06%)

ALXN

Alexion

$116.82

-1.9 (-1.60%)

AMGN

Amgen

$160.41

-1.63 (-1.01%)

BAX

Baxter

$52.88

-0.01 (-0.02%)

GSK

GlaxoSmithKline

$40.78

0.07 (0.17%)

HZNP

Horizon Pharma

$14.99

-0.25 (-1.64%)

MNK

Mallinckrodt

$43.52

-1.41 (-3.14%)

MRK

Merck

$61.89

-0.66 (-1.06%)

AUPH

Aurinia Pharmaceuticals

$7.11

0.11 (1.57%)

NXTM

NxStage Medical

$27.90

-0.19 (-0.68%)

PLX

Protalix

$1.02

0.02 (2.00%)

RTRX

Retrophin

$18.47

-0.37 (-1.96%)

SNY

Sanofi

$44.09

-0.7 (-1.56%)

SHPG

Shire

$171.94

0.08 (0.05%)

TKPYY

Takeda Pharmaceutical Co. Ltd.

$24.29

0.215 (0.89%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Apr

  • 24

    Apr

  • 26

    Apr

  • 27

    Apr

  • 27

    Apr

  • 28

    Apr

  • 02

    May

  • 02

    May

  • 03

    May

  • 04

    May

  • 07

    May

  • 08

    May

  • 08

    May

  • 09

    May

  • 10

    May

  • 27

    May

  • 06

    Jun

  • 09

    Jun

  • 14

    Jun

  • 26

    Jun

  • 19

    Jul

  • 14

    Aug

  • 23

    Oct

ABBV

AbbVie

$63.82

0.04 (0.06%)

, ALXN

Alexion

$116.82

-1.9 (-1.60%)

04:55
04/22/17
04/22
04:55
04/22/17
04:55
Conference/Events
European Association for the Study of Liver »

International Liver…

ABBV

AbbVie

$63.82

0.04 (0.06%)

ALXN

Alexion

$116.82

-1.9 (-1.60%)

BAX

Baxter

$52.88

-0.01 (-0.02%)

CPHD

Cepheid

GALT

Galectin Therapeutics

$3.09

-0.14 (-4.33%)

GILD

Gilead

$65.93

-0.57 (-0.86%)

ICPT

Intercept

$107.89

0.7 (0.65%)

JWA

John Wiley & Sons; also tag JWB

NVS

Novartis

$73.40

-0.22 (-0.30%)

OSUR

OraSure

$12.67

0.03 (0.24%)

SIEGY

Siemens

$67.34

-0.197 (-0.29%)

VTL

Vital Therapies

$3.50

-0.1 (-2.78%)

ARWR

Arrowhead

$1.52

0.01 (0.66%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Apr

  • 22

    Apr

  • 26

    Apr

  • 27

    Apr

  • 27

    Apr

  • 02

    May

  • 02

    May

  • 02

    May

  • 03

    May

  • 03

    May

  • 16

    May

  • 06

    Jun

  • 26

    Jun

  • 23

    Oct

RGEN

Repligen

$35.06

-0.78 (-2.18%)

19:19
04/21/17
04/21
19:19
04/21/17
19:19
Initiation
Repligen initiated at First Analysis »

Repligen initiated with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 04

    May

  • 30

    May

  • 06

    Jun

TWTR

Twitter

$14.63

-0.02 (-0.14%)

18:07
04/21/17
04/21
18:07
04/21/17
18:07
Periodicals
Homeland Security investigates potential abuse in Twitter case, Reuters says »

The U.S. Department of…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GOOG

Alphabet

$843.19

1.54 (0.18%)

, GOOGL

Alphabet Class A

$858.95

-1.13 (-0.13%)

17:46
04/21/17
04/21
17:46
04/21/17
17:46
Periodicals
Waymo:Uber misled court on Levandowski using LIDAR secrets, Bloomberg says »

According to Bloomberg,…

GOOG

Alphabet

$843.19

1.54 (0.18%)

GOOGL

Alphabet Class A

$858.95

-1.13 (-0.13%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Apr

  • 02

    May

  • 22

    May

CDNA

CareDx

$1.00

0.05 (5.26%)

17:33
04/21/17
04/21
17:33
04/21/17
17:33
Hot Stocks
CareDx receives expected letter from Nasdaq »

CareDx announced that, as…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GBX

Greenbrier

$44.45

-0.2 (-0.45%)

17:33
04/21/17
04/21
17:33
04/21/17
17:33
Hot Stocks
Greenbrier CEO intends to sell one-half of his position in company stock »

The CEO of The Greenbrier…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    May

CDNA

CareDx

$1.00

0.05 (5.26%)

17:32
04/21/17
04/21
17:32
04/21/17
17:32
Earnings
CareDx backs FY17 revenue view $45M-$50M, consensus $47.62M »

Revenue view excludes any…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CDNA

CareDx

$1.00

0.05 (5.26%)

17:32
04/21/17
04/21
17:32
04/21/17
17:32
Earnings
CareDx reports Q4 adjusted EPS (13c), consensus (18c) »

Reports Q4 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AMMA

Alliance MMA

$1.69

-0.05 (-2.87%)

17:32
04/21/17
04/21
17:32
04/21/17
17:32
Hot Stocks
Alliance MMA announces shareholder filed lawsuit against the company »

Alliance MMA announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CDNA

CareDx

$1.00

0.05 (5.26%)

17:30
04/21/17
04/21
17:30
04/21/17
17:30
Hot Stocks
CareDx names Michael Bell CFO »

CareDx announced the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NVO

Novo Nordisk

$35.88

-0.52 (-1.43%)

, XOMA

XOMA

$7.73

0.26 (3.48%)

17:22
04/21/17
04/21
17:22
04/21/17
17:22
Hot Stocks
Novo Nordisk terminates exclusive license agreement with XOMA »

On April 20, XOMA (XOMA)…

NVO

Novo Nordisk

$35.88

-0.52 (-1.43%)

XOMA

XOMA

$7.73

0.26 (3.48%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    May

  • 07

    May

  • 18

    May

  • 06

    Jun

HH

Hooper Holmes

$0.72

-0.1973 (-21.44%)

17:21
04/21/17
04/21
17:21
04/21/17
17:21
Hot Stocks
Breaking Hot Stocks news story on Hooper Holmes »

John Pappajohn reports…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FBMS

First Bancshares

$28.00

0.15 (0.54%)

17:14
04/21/17
04/21
17:14
04/21/17
17:14
Earnings
First Bancshares reports Q1 EPS 12 c with items, consensus 35c »

Reports Q1 provision for …

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DRWI

DragonWave

$1.23

-0.025 (-2.00%)

17:04
04/21/17
04/21
17:04
04/21/17
17:04
Hot Stocks
DragonWave did not regain compliance with Nasdaq listing standards »

DragonWave announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SHLD

Sears

$13.39

-0.25 (-1.83%)

17:02
04/21/17
04/21
17:02
04/21/17
17:02
Hot Stocks
Sears establishes special committee to market certain real estate properties »

Sears Holdings said its…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    May

SHLD

Sears

$13.39

-0.25 (-1.83%)

17:00
04/21/17
04/21
17:00
04/21/17
17:00
Hot Stocks
Sears names Rob Riecker CFO »

Sears announced that Rob…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    May

UAL

United Continental

$69.56

-0.24 (-0.34%)

17:00
04/21/17
04/21
17:00
04/21/17
17:00
Hot Stocks
UAL: employee incentive opportunity to be tied to 'customer experience' »

United Continental said…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SHLD

Sears

$13.39

-0.25 (-1.83%)

17:00
04/21/17
04/21
17:00
04/21/17
17:00
Earnings
Sears sees FY17 net income $185M-$285M »

"The retail…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    May

SHLD

Sears

$13.39

-0.25 (-1.83%)

16:59
04/21/17
04/21
16:59
04/21/17
16:59
Hot Stocks
Sears raises annualized cost savings target to $1.25B from $1B »

Sears Holdings provided…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    May

LTBR

Lightbridge

$1.25

-0.06 (-4.58%)

16:51
04/21/17
04/21
16:51
04/21/17
16:51
Hot Stocks
CEO of Lightbridge Seth Grae reports 5.1% stake in company »

As of March 22, Seth…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

IONS

Ionis Pharmaceuticals

$44.26

1.35 (3.15%)

16:46
04/21/17
04/21
16:46
04/21/17
16:46
Syndicate
Breaking Syndicate news story on Ionis Pharmaceuticals »

Ionis Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Apr

  • 24

    May

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.